SG11201507519RA - Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) - Google Patents
Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)Info
- Publication number
- SG11201507519RA SG11201507519RA SG11201507519RA SG11201507519RA SG11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA SG 11201507519R A SG11201507519R A SG 11201507519RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolonaphthyridinone
- derivatives
- methionine aminopeptidase
- metap2 inhibitors
- aminopeptidase type
- Prior art date
Links
- 101710181812 Methionine aminopeptidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YJTVMKYUFDOGJU-UHFFFAOYSA-N pyrazolo[4,3-b][1,8]naphthyridin-3-one Chemical class N1=NC(C=2C1=CC=1C=CC=NC1N2)=O YJTVMKYUFDOGJU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305365 | 2013-03-25 | ||
| PCT/EP2014/055719 WO2014154586A1 (en) | 2013-03-25 | 2014-03-21 | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507519RA true SG11201507519RA (en) | 2015-10-29 |
Family
ID=48040135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507519RA SG11201507519RA (en) | 2013-03-25 | 2014-03-21 | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9856257B2 (en) |
| EP (1) | EP2978764B1 (en) |
| JP (1) | JP2016515541A (en) |
| KR (1) | KR20150135406A (en) |
| CN (1) | CN105246893B (en) |
| AU (1) | AU2014243257A1 (en) |
| BR (1) | BR112015024189A2 (en) |
| CA (1) | CA2907532A1 (en) |
| DK (1) | DK2978764T3 (en) |
| ES (1) | ES2633440T3 (en) |
| IL (1) | IL241447A0 (en) |
| MX (1) | MX2015013740A (en) |
| PL (1) | PL2978764T3 (en) |
| PT (1) | PT2978764T (en) |
| RU (1) | RU2015145479A (en) |
| SG (1) | SG11201507519RA (en) |
| WO (1) | WO2014154586A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| WO2016090380A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2969597C (en) | 2014-12-06 | 2023-10-24 | Intra-Cellular Therapies, Inc. | 1h-pyrazolo[4,3-c][1,5]naphthyridin-4(5h)-one compounds and their use as pde2 inhibitors |
| WO2017046606A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds |
| TWI782056B (en) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | A fused ring derivative having a mgat2 inhibitoy activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2622605A1 (en) * | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
| US8642597B2 (en) | 2007-08-27 | 2014-02-04 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| CN103748094B (en) * | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | Tricyclic sulfonamide compound and preparation and application thereof |
| DK2573073T3 (en) | 2011-09-26 | 2015-01-19 | Sanofi Sa | Pyrazolquinolinonderivater, their preparation and therapeutic use thereof |
| US20140235616A1 (en) | 2011-09-26 | 2014-08-21 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
-
2014
- 2014-03-21 AU AU2014243257A patent/AU2014243257A1/en not_active Abandoned
- 2014-03-21 CA CA2907532A patent/CA2907532A1/en not_active Abandoned
- 2014-03-21 JP JP2016503675A patent/JP2016515541A/en active Pending
- 2014-03-21 PT PT147115240T patent/PT2978764T/en unknown
- 2014-03-21 CN CN201480029260.XA patent/CN105246893B/en not_active Expired - Fee Related
- 2014-03-21 DK DK14711524.0T patent/DK2978764T3/en active
- 2014-03-21 WO PCT/EP2014/055719 patent/WO2014154586A1/en active Application Filing
- 2014-03-21 MX MX2015013740A patent/MX2015013740A/en unknown
- 2014-03-21 ES ES14711524.0T patent/ES2633440T3/en active Active
- 2014-03-21 KR KR1020157030319A patent/KR20150135406A/en not_active Application Discontinuation
- 2014-03-21 US US14/778,948 patent/US9856257B2/en not_active Expired - Fee Related
- 2014-03-21 SG SG11201507519RA patent/SG11201507519RA/en unknown
- 2014-03-21 PL PL14711524T patent/PL2978764T3/en unknown
- 2014-03-21 EP EP14711524.0A patent/EP2978764B1/en not_active Not-in-force
- 2014-03-21 RU RU2015145479A patent/RU2015145479A/en not_active Application Discontinuation
- 2014-03-21 BR BR112015024189A patent/BR112015024189A2/en not_active Application Discontinuation
-
2015
- 2015-09-10 IL IL241447A patent/IL241447A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016515541A (en) | 2016-05-30 |
| BR112015024189A2 (en) | 2017-07-18 |
| PL2978764T3 (en) | 2017-09-29 |
| ES2633440T3 (en) | 2017-09-21 |
| US9856257B2 (en) | 2018-01-02 |
| CA2907532A1 (en) | 2014-10-02 |
| EP2978764B1 (en) | 2017-04-19 |
| WO2014154586A1 (en) | 2014-10-02 |
| DK2978764T3 (en) | 2017-07-31 |
| MX2015013740A (en) | 2016-02-29 |
| RU2015145479A (en) | 2017-05-02 |
| CN105246893B (en) | 2017-10-27 |
| CN105246893A (en) | 2016-01-13 |
| AU2014243257A1 (en) | 2015-10-15 |
| KR20150135406A (en) | 2015-12-02 |
| PT2978764T (en) | 2017-07-17 |
| EP2978764A1 (en) | 2016-02-03 |
| IL241447A0 (en) | 2015-11-30 |
| US20160060265A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221466A1 (en) | Bipyrazole derivatives as jak inhibitors jak | |
| AR095266A1 (en) | TETRACICLIC BROMODOMINES INHIBITORS | |
| HK1219475A1 (en) | Neprilysin inhibitors | |
| HK1216531A1 (en) | Novel inhibitors | |
| GB201317609D0 (en) | Inhibitor compounds | |
| EP2991654A4 (en) | Novel compounds that are erk inhibitors | |
| HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
| IL241447A0 (en) | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) | |
| EP2961403A4 (en) | Heterocyclic inhibitors of the sodium channel | |
| IL244029A0 (en) | Deoxycytidine kinase inhibitors | |
| HK1222582A1 (en) | Agent for improving bladder-urethera dyssynergia | |
| DOS2014000147S (en) | PACKAGING / (PART OF) | |
| UA31214S (en) | PACKAGING FOR CIGARETTES | |
| GB201321328D0 (en) | Inhibitor compounds | |
| UA31604S (en) | PACKAGING FOR CIGARETTES | |
| UA29169S (en) | PACKAGING FOR CIGARETTES | |
| GB201305503D0 (en) | Inhibitor |